186 related articles for article (PubMed ID: 16728325)
21. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
Miao HQ; Hu K; Jimenez X; Navarro E; Zhang H; Lu D; Ludwig DL; Balderes P; Zhu Z
Biochem Biophys Res Commun; 2006 Jun; 345(1):438-45. PubMed ID: 16682007
[TBL] [Abstract][Full Text] [Related]
22. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
23. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
[TBL] [Abstract][Full Text] [Related]
24. Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice.
Hiratsuka S; Nakao K; Nakamura K; Katsuki M; Maru Y; Shibuya M
Mol Cell Biol; 2005 Jan; 25(1):346-54. PubMed ID: 15601855
[TBL] [Abstract][Full Text] [Related]
25. Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165.
Zhang Y; Furumura M; Morita E
Growth Factors; 2008 Jun; 26(3):125-31. PubMed ID: 18569020
[TBL] [Abstract][Full Text] [Related]
26. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway.
Vogel C; Bauer A; Wiesnet M; Preissner KT; Schaper W; Marti HH; Fischer S
J Cell Physiol; 2007 Jul; 212(1):236-43. PubMed ID: 17311300
[TBL] [Abstract][Full Text] [Related]
27. VEGFR2 (KDR/Flk1) signaling mediates axon growth in response to semaphorin 3E in the developing brain.
Bellon A; Luchino J; Haigh K; Rougon G; Haigh J; Chauvet S; Mann F
Neuron; 2010 Apr; 66(2):205-19. PubMed ID: 20434998
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action.
Nowacka MM; Obuchowicz E
Neuropeptides; 2012 Feb; 46(1):1-10. PubMed ID: 21719103
[TBL] [Abstract][Full Text] [Related]
29. VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner.
Vartanian A; Stepanova E; Grigorieva I; Solomko E; Baryshnikov A; Lichinitser M
Melanoma Res; 2011 Apr; 21(2):91-8. PubMed ID: 21389833
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E.
Shibuya M
Cancer Sci; 2003 Sep; 94(9):751-6. PubMed ID: 12967471
[TBL] [Abstract][Full Text] [Related]
31. The endothelial adaptor molecule TSAd is required for VEGF-induced angiogenic sprouting through junctional c-Src activation.
Gordon EJ; Fukuhara D; Weström S; Padhan N; Sjöström EO; van Meeteren L; He L; Orsenigo F; Dejana E; Bentley K; Spurkland A; Claesson-Welsh L
Sci Signal; 2016 Jul; 9(437):ra72. PubMed ID: 27436360
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential.
Zachary I
Neurosignals; 2005; 14(5):207-21. PubMed ID: 16301836
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
Casanovas O; Hicklin DJ; Bergers G; Hanahan D
Cancer Cell; 2005 Oct; 8(4):299-309. PubMed ID: 16226705
[TBL] [Abstract][Full Text] [Related]
34. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
Getmanova EV; Chen Y; Bloom L; Gokemeijer J; Shamah S; Warikoo V; Wang J; Ling V; Sun L
Chem Biol; 2006 May; 13(5):549-56. PubMed ID: 16720276
[TBL] [Abstract][Full Text] [Related]
35. Comparative integromics on VEGF family members.
Katoh Y; Katoh M
Int J Oncol; 2006 Jun; 28(6):1585-9. PubMed ID: 16685460
[TBL] [Abstract][Full Text] [Related]
36. Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells.
Basi DL; Lee SW; Helfman S; Mariash A; Lunos SA
Mol Med Rep; 2010; 3(3):399-403. PubMed ID: 21472253
[TBL] [Abstract][Full Text] [Related]
37.
Chandler KB; Leon DR; Kuang J; Meyer RD; Rahimi N; Costello CE
J Biol Chem; 2019 Aug; 294(35):13117-13130. PubMed ID: 31308178
[TBL] [Abstract][Full Text] [Related]
38. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases.
Shibuya M
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells.
Ewan LC; Jopling HM; Jia H; Mittar S; Bagherzadeh A; Howell GJ; Walker JH; Zachary IC; Ponnambalam S
Traffic; 2006 Sep; 7(9):1270-82. PubMed ID: 17004325
[TBL] [Abstract][Full Text] [Related]
40. Structural investigation of the VEGF receptor interaction with a helical antagonist peptide.
Diana D; Di Stasi R; De Rosa L; Isernia C; D'Andrea LD; Fattorusso R
J Pept Sci; 2013 Apr; 19(4):214-9. PubMed ID: 23420665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
